GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PepGen Inc (NAS:PEPG) » Definitions » Total Payout Ratio

PepGen (PepGen) Total Payout Ratio : 1.08 (As of Jun. 22, 2024)


View and export this data going back to 2022. Start your Free Trial

What is PepGen Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

PepGen's current Total Payout Ratio is 1.08.

PepGen Total Payout Ratio Historical Data

The historical data trend for PepGen's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PepGen Total Payout Ratio Chart

PepGen Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Payout Ratio
- - 1.65 -

PepGen Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 4.82

Competitive Comparison of PepGen's Total Payout Ratio

For the Biotechnology subindustry, PepGen's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PepGen's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PepGen's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where PepGen's Total Payout Ratio falls into.


PepGen Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

PepGen's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -78.626
=0.00

PepGen's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 86.778 + 0) / -18.02
=4.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PepGen Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of PepGen's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

PepGen (PepGen) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PepGen Inc (NAS:PEPG) » Definitions » Total Payout Ratio
Comparable Companies
ADAP CTXR LBPH PRAX TALS XFOR LRMR GALT TSVT TNYA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
321 Harrison Avenue, 8th Floor, Boston, MA, USA, 02118
Website
https://www.pepgen.com
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Executives
James G Mcarthur director, officer: President and CEO NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Jaya Goyal officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
James E Flynn 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Laurie Keating director 300 THIRD STREET, CAMBRIDGE MA 02142
Christopher Ashton director PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Management Company, L.p. (series C) 10 percent owner, other: *Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Michelle L Mellion officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Noel Donnelly officer: Chief Financial Officer PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Niels Svenstrup officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Sonia Bracegirdle officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Mgmt V, L.p. 10 percent owner, other: *Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Private Design Fund V, L.p. 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Oxford Science Enterprises Plc 10 percent owner 46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT